Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3644516
Max Phase: Preclinical
Molecular Formula: C10H12N2O5
Molecular Weight: 240.22
Molecule Type: Small molecule
Associated Items:
ID: ALA3644516
Max Phase: Preclinical
Molecular Formula: C10H12N2O5
Molecular Weight: 240.22
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: Cc1cn2c(nc1=O)O[C@H]1C(O)[C@@H](CO)O[C@H]12
Standard InChI: InChI=1S/C10H12N2O5/c1-4-2-12-9-7(6(14)5(3-13)16-9)17-10(12)11-8(4)15/h2,5-7,9,13-14H,3H2,1H3/t5-,6?,7+,9-/m1/s1
Standard InChI Key: WLLOAUCNUMYOQI-AOXOCZDOSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 240.22 | Molecular Weight (Monoisotopic): 240.0746 | AlogP: -1.44 | #Rotatable Bonds: 1 |
Polar Surface Area: 93.81 | Molecular Species: NEUTRAL | HBA: 7 | HBD: 2 |
#RO5 Violations: 0 | HBA (Lipinski): 7 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 12.98 | CX Basic pKa: | CX LogP: -0.87 | CX LogD: -0.87 |
Aromatic Rings: 1 | Heavy Atoms: 17 | QED Weighted: 0.62 | Np Likeness Score: 1.49 |
1. (2014) Methotrexate adjuvants to reduce toxicity and methods for using the same, |
Source(1):